Glycolytic metabolism confers resistance to combined all-trans retinoic acid and arsenic trioxide-induced apoptosis in HL60ρ0 cells

Leukemia Research

Volumn 32, Issue 2, 2008, Pages 327-333

  Herst, Patries M ^a   Hesketh, Elizabeth L ^a   Ritchie, David S ^b   Berridge, Michael V ^a  

^a MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Apoptosis; ATO; ATRA; Differentiation; Drug resistance; Fas; Glycolytic metabolism

Indexed keywords

ARSENIC TRIOXIDE; CD15 ANTIGEN; FAS ANTIGEN; RETINOIC ACID;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL STRAIN HL 60; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; FLUORESCENCE ACTIVATED CELL SORTING; GLYCOLYSIS; HUMAN; HUMAN CELL; KNOCKOUT GENE; LEUKEMIA CELL; MITOCHONDRIAL GENE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RESPIRATORY BURST;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CELL DIFFERENTIATION; DRUG RESISTANCE, NEOPLASM; GENES, MITOCHONDRIAL; GLYCOLYSIS; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; OXIDES; TRETINOIN;

EID: 38949162218     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.04.014     Document Type: Article

References (37)

1. Warburg O. Ist die Glykolyse spezifisch für die Tumoren?. Biochem Z 204 (1929) 482-483
2. Pedersen P.L. Tumor mitochondria and the bioenergetics of cancer cells. Prog Exp Tumor Res 22 (1978) 190-274
3. Kunkel M., Reichert T.E., Benz P., Lehr H.A., Jeong J.H., Wieand S., Bartenstein P., Wagner W., and Whiteside T.L. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 97 4 (2003) 1015-1024
4. Kurokawa T., Yoshida Y., Kawahara K., Tsuchida T., Okazawa H., Fujibayashi Y., Yonekura Y., and Kotsuji F. Expression of GLUT-1 glucose transfer, cellular proliferation and grade of tumour correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer 109 6 (2004) 926-932
5. Macheda M.L., Rogers S., and Best J.D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 202 3 (2005) 654-662
6. + diffusion to the acidic pH of tumors. Neoplasia 5 2 (2003) 135-145
7. Fantin V.R., St-Pierre J., and Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9 (2006) 425-434
8. Larm J.A., Vaillant F., Linnane A.W., and Lawen A. Up-regulation of the plasma membrane oxidoreductase as a prerequisite for the viability of human Namalwa rho 0 cells. J Biol Chem 269 48 (1994) 30097-30100
9. Herst P.M., Tan A.S., Scarlett D.-J.G., and Berridge M.V. Cell surface oxygen consumption by mitochondrial gene knockout cells. Biochim Biophys Acta 1656 2-3 (2004) 79-87
10. Scarlett D.-J., Herst P., Tan A., Prata C., and Berridge M. Mitochondrial gene-knockout (rho0) cells: a versatile model for exploring the secrets of trans-plasma membrane electron transport. Biofactors 20 4 (2004) 199-206
11. Herst P.M., and Berridge M.V. Cell surface oxygen consumption: a major contributor to cellular oxygen consumption in glycolytic cancer cell lines. Biochim Biophys Acta 1767 (2007) 170-177
12. Robey I.F., Lien A.D., Welsh S.J., Baggett B.K., and Gillies R.J. Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia 7 4 (2005) 324-330
13. Simonnet H., Alazard N., Pfeiffer K., Gallou C., Béroud C., Demont J., Bouvier R., Schägger H., and Godinot C. Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis 23 5 (2002) 759-768
14. Gatenby R.A., and Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat Revi Cancer 4 (2004) 891-899
15. Park S.Y., Chang I., Kim J.Y., Kang S.W., Pak S.H., Singh K., and Lee M.S. Resistance of mitochondrial DNA-depleted cells against cell death: role of mitochondrial superoxide dismutase. J Biol Chem 279 9 (2004) 7512-7520
16. Singh K.K., Russell J.R., Sigala B., Zhang Y., Williams J., and Keshav K.F. Mitochondrial DNA determines the cellular response to cancer therapeutic agents. Oncogene 18 (1999) 6641-6646
17. 0 cells show preferential differentiation into monocytes/macrophages. Leuk Res 29 10 (2005) 1163-1170
18. Niu C., Yan H., Yu T., Sun H.P., Liu J.X., Li X.S., Wu W., Zhang F.Q., Chen Y., Zhou L., Li J.M., Zeng X.Y., Yang R.R.O., Yuan M.M., Ren M.Y., Gu F.Y., Cao Q., Gu B.W., Su X.Y., Chen G.Q., Xiong S.M., Zhang T.D., Waxman S., Wang Z.Y., Chen Z., Hu J., Shen Z.X., and Chen S.J. Studies on the treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94 10 (1999) 3315-3324
19. Tallman M.S., Nabhan C., Feusner J.H., and Rowe J. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 99 3 (2002) 759-767
20. 3) in the treatment of acute promyelocytic leukemia (APL) II: clinical efficacy and pharmacokinetics in relapsed patients. Blood 89 9 (1997) 3354-3360
21. Wang G., Li W., Cui J., Gao C., Jiang Z., Song Y., Yuan Y., Liu Z., and Cai L. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide and low dose all-trans retinoic acid. Hematol Oncol 22 2 (2004) 63-71
22. 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 101 15 (2004) 5328-5335
23. Estey E., Garcia-Manero G., Ferrajoli A., Faderl S., Verstovsek S., Jones D., and Kantarjian H. Use of all-trans retinoic acid + arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood (2005)
24. Volpi E.V., Vatcheva R., Labella T., and Gan S.U. More detailed characterization of some of the HL60 karyotypic features by fluorescence in situ hybridization. Cancer Gen Cytogen 87 2 (1996) 103-106
25. Dalton W.T., Ahearn M.J., McCredie K.B., Freireich E.J., Stass S.A., and Trujillo J.M. HL-60 Cell line was derived from a patient with FAB-M2 and not FAB-M3. Blood 71 1 (1988) 242-247
26. King M.P., and Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 246 4929 (1989) 500-503
27. Tan A.S., and Berridge M.V. Superoxide produced by activated neutrophils efficiently reduces the tetrazolium salt, WST-1 to produce a soluble formazan: a simple colorimetric assay for measuring respiratory burst activation and for screening anti-inflammatory agents. J Immunol Methods 238 1-2 (2000) 59-68
28. 2/M cell cycle arrest, activation of caspase 8 or caspase 9, and synergy with APO/TRAIL. Blood 101 10 (2003) 4078-4087
29. Wolf D., and Rotter V. Major deletions in the gene encoding p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci USA 82 (1985) 790-794
30. Breitman T.R., Selonick S.E., and Collins S.J. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 77 (1980) 2936-2940
31. Salih H.R., and Kiener P.A. Alterations in Fas (CD95/Apo1) and Fas ligand (CD178) expression in acute promyelocytic leukemia during treatment with ATRA. Leuk Lymph 45 1 (2004) 55-59
32. Salih H.R., Starling G.C., Branl S.F., Pelka-Fleischer R., Haferlach T., and Hiddemann W. Differentiation of promyelocytic leukemia: alterations in Fas (CD95/APO-1) and Fas ligand (CD178) expression. Br J Haematol 117 (2002) 76-85
33. Rumi C., Rutella S., Lucia B.M., Teofili L., De S.V., and Leone G. APO-1/Fas receptor (CD95) is non-functionally expressed in acute promyelocytic leukemias. Eur J Histochem 41 (1997) 43-44
34. Ohashi M., Iwase M., and Nagumo M. Changes in susceptibility to Fas-mediated apoptosis during differentiation of HL60 cells. J Leucocyte Biol 67 (2000) 374-380
35. Zhu J., Okumura H., Ohtake S., Nakamura S., and Nakao S. Arsenic trioxide induces apoptosis in leukemia/lymphoma cell lines via CD95/CD95L system. Oncol Rep 10 3 (2003) 705-709
36. Zhu J., Okumura H., Ohtake S., Nakamura S., and Nakao S. The molecular mechanisms of arsenic trioxide-induced apoptosis and oncosis in leukemia/lymphoma cell lines. Acta Haematol 110 (2003) 1-10
37. Rojewski M.T., Korper S., Thiel E., and Schrezenmeier H. Arsenic trioxide-induced apoptosis is independent of CD95 in lymphatic cell lines. Oncol Rep 11 (2004) 509-513